1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Wanbury Limited

Wanbury Limited

179.90
INR
-6.30
(-3.38%)
16.20EPS
16.59P/E
9.76BMarket Cap
Nov 12Next Earn
2013 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
264.17
125.15
211.96
206.29
155.19
163.11
151.3
154.8
157.45
152.38
175.52
181.18
189.75
196.62
Basic EPS, GAAP
-50.19
1.6
-3.58
29.8
-13.49
-10.48
26.9
-5.04
25.29
-3.18
17.1
9.32
19.49
16.84
Free Cash Flow per Basic Share
42.65
20.11
21.56
20.85
13.7
12.53
18.42
6.67
12.58
6.06
1.44
8
9.13
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-27.59
-97.12
-112.85
-66.01
-77.86
-88.23
-57.39
-62.46
-7.17
-10.03
8.53
18.09
41.34
- -
Tangible Book Value per Share
-157.69
-97.29
-113.37
-66.39
-78.19
-88.47
-57.56
-62.55
-7.2
-10.06
8.45
18.02
40.57
- -
Basic Weighted Avg Shares
17
20
20
21
24
24
24
25
32
33
33
33
34
33
Sales/Revenue/Turnover
4,591
2,499
4,233
4,293
3,681
3,869
3,626
3,871
5,072
4,982
5,745
5,935
6,439
6,527
Operating Margin (%)
-11.7
7.66
6.05
1.95
-2.67
1.72
16.11
3.81
5.75
2.38
9.96
11.84
41.71
12.85
Depreciation Expense
226
48
91
103
103
100
97
98
114
124
130
134
143
147
Net Income, GAAP
-872
32
-71
620
-320
-248
645
-126
815
-104
560
305
661
559
Effective Tax Rate (%)
- -
28.46
- -
0.61
- -
- -
0.32
- -
- -
- -
0.68
- -
- -
- -
Profit Margin (%)
-19
1.28
-1.69
14.45
-8.7
-6.42
17.78
-3.26
16.06
-2.09
9.74
5.14
10.27
8.56
Working Capital
-2,575
-837
-2,234
-2,102
-2,706
-2,634
-2,174
-2,541
-1,866
-1,962
-521
188
375
- -
LT Debt
3,103
2,705
2,082
1,537
990
1,230
995
763
41
24
859
1,611
1,494
- -
Total Equity
-213
-1,673
-2,254
-1,533
-1,847
-2,093
-1,435
-1,562
-234
-328
279
593
1,445
- -
Return on Invested Capital (%)
- -
1.2
- -
-2.59
- -
- -
159.48
- -
- -
- -
75.66
- -
- -
- -
Return on Capital (%)
- -
5.83
- -
53.93
- -
- -
135.73
- -
- -
- -
77.39
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
70.01
64.93
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
750
- -
LT Borrowings
- -
1,472
- -
LT Finance Leases
- -
22
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
7,926
7,776
9,760

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,386
- -
Cash, Cash Equivalents & STI
- -
103
- -
Accounts Receivable, Net
- -
1,433
- -
Inventories
- -
506
- -
Total Current Liabilities
- -
2,010
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
750
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.51%
5.16%
143.71%
Free Cash Flow
44.49%
98.3%
18.22%
Net Income, GAAP
-304.69%
-285.23%
116.62%
Sales/Revenue/Turnover
4.91%
11.27%
8.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,311
1,612
1,335
1,720
5,935
2026
1,632
1,601
1,624
1,646
6,439
2027
1,656
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.32
2.44
0.38
6.18
9.32
2026
4.12
4.58
4.52
7.26
19.49
2027
0.93
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pradeep Patni
Full Time Employees
1,200
Sector
Health technology
Industry
Pharmaceuticals: major
Address
BSEL Tech Park, B-Wing Mumbai MA India 400703
IPO Date
Feb 24, 1992
Website
wanbury.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Wanbury Limited manufactures and markets active pharmaceutical ingredients and formulations primarily for therapeutic areas including anti-infectives, pain and analgesics, respiratory conditions, gastroenterology, gynecology, rheumatology, and the central nervous system. The company produces active pharmaceutical ingredients such as Metformin Hydrochloride and its DC granules, Sertraline Hydrochloride, Tramadol Hydrochloride, Ketamine Hydrochloride, Diphenhydramine Hydrochloride and Citrate, Mefenamic Acid, Paroxetine Hydrochloride Hemihydrate, Dextromethorphan Hydrobromide, Rivaroxaban, and Sitagliptin Phosphate Monohydrate; it supplies over 40 APIs, excipients, and intermediates with regulatory filings including USDMF, CEP, EDQM, and WHO GMP certifications. Wanbury offers branded formulations like Adtrol XT Tablet, Augtum injection, Cdense Total Tablet, and Cemax-Cef injection, alongside iron supplement WANBURY C RED launched in 2025 to combat anemia; it serves regulated markets including the US, Europe, Brazil, Korea, India, Mexico, Canada, and China, exporting to over 50 countries with facilities in Patalganga, Tanuku, and Tarapur, two of which are USFDA-approved. Founded in 1988 and headquartered in Navi Mumbai, India, Wanbury changed its name from an earlier entity to Wanbury Limited in 2004 following mergers with Wander Limited and Pearl Organics Limited. The company employs approximately 1,491 people and operates a subsidiary, Ningxia Wanbury Fine Chemicals Co. Ltd. in China for raw material sourcing. It maintains high-tech manufacturing facilities equipped for quality API and formulation production. Recent developments include consolidated net sales reaching Rs 172 crore in March 2025, up 23.38% year-over-year, and standalone September 2025 net sales at Rs 160.06 crore with EBITDA up 20.06%; the company reported strong quarterly revenue growth of 29.45% in Q4 2024-2025 alongside net profit margins of 11.65%. Wanbury continues strategic expansions in regulated markets as the largest exporter of Tramadol to the US and a leading global producer of Metformin exceeding 8,500 tons annually. No major acquisitions, partnerships, or funding rounds have been announced in the last 1-2 years.